Please assess the completion status of the following clinical trial:

Trial Title: Mylan Insulin Aspart Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Written and signed informed consent.~2. Clinical diagnosis of type 1 diabetes mellitus for at least 6 months prior to screening.~3. Subject is able and willing to comply with the requirements of the study protocol.~Exclusion Criteria~1. History or presence of a medical condition or disease that in the Investigator's opinion would place the subject at an unacceptable risk from study participation.~2. History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the study, OR history of significant allergic drug reactions.~3. Any clinically significant abnormality in electrocardiogram or safety laboratory tests.~4. Any elective surgery requiring hospitalization planned during the study period.~5. History of a significant medical condition, such as unstable angina, myocardial infarction, stroke or transient ischemic attack in the 6 months before screening.~6. Subjects with major depressive illness in the last 3 years.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MYL-1601D Product (100 U/mL) (Type: ACTIVE_COMPARATOR): None
- FlexPen NovoLog® (100 U/mL) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).